Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
http://www.freshnews.com/news/872214/european-commission-approves-gilead-s-vitekta-integrase-inhibitor-treatment-hiv-1-infec
http://www.freshnews.com/news/872214/european-commission-approves-gilead-s-vitekta-integrase-inhibitor-treatment-hiv-1-infec
No comments:
Post a Comment